Depression and Anxiety Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For people with depression:
- People who have been diagnosed with major depressive disorder according to standard diagnostic guidelines (DSM-5)
- People who are not currently taking any antidepressant medication
For healthy participants (people without depression):
- People with a low level of a marker of inflammation in the blood called C-reactive protein (CRP), specifically at or below 1 mg/l
- People who are not currently taking any antidepressant medication
- People who do not currently have any diagnosed mental health condition
Who may not be able to join:
- People who have been diagnosed with schizophrenia, schizoaffective disorder, bipolar disorder, or dementia
- People with a current or past history of alcohol or drug dependence
- People with diseases affecting the brain or nervous system
- People with neurological conditions
- People with unexplained or undiagnosed skin lesions, or a history of melanoma (a type of skin cancer)
- People who have been diagnosed with glaucoma (a condition affecting the eyes), either narrow-angle or wide-angle
- People with bronchial asthma
- People with a history of peptic ulcer disease (stomach ulcers)
- People with a history of seizures
- People with any serious physical health condition
- People with a current infection or a long-term inflammatory condition, such as rheumatoid arthritis or inflammatory bowel disease
- People who are pregnant or breastfeeding
- People with a body mass index (BMI) of 40 or higher (sometimes called class 3 obesity)
- People currently taking certain medications, including reserpine (used for blood pressure), tricyclic antidepressants, certain MAO inhibitor medications, anti-Parkinson's drugs, sympathomimetic drugs, or tetrabenazine (confirm specific medications with the trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Woo Ri Chae, MD MSc, Charite University, Berlin, Germany
Phone: +49 30 450 517625
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The change in response bias (logb) after L-dopa/Carbidopa compared to placebo in the Probabilistic Reward Task (PRT).; The change in mean gait speed [m/s] after L-dopa/Carbidopa compared to placebo in the dual task.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.